Prospects for the development of adjuvant therapy for non-small cell lung cancer

The standard approach for stage IB and IIIIIA non-small cell lung cancer (NSCLC), associated with the high risk of relapse, after total lung resection is adjuvant chemotherapy, nowadays. The 5-year survival benefit for this approach is about 5%, and the risk of relapse reduces from 11 to 15%, depend...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	K. K. Laktionov, A. M. Kazakov, E. V. Reutova, M. S. Ardzinba, A. L. Arzumanian
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	non-small cell lung cancer adjuvant targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0ce8e5769b2f4663b26654a8a7d6d7e7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0ce8e5769b2f4663b26654a8a7d6d7e7
record_format	dspace
spelling	oai:doaj.org-article:0ce8e5769b2f4663b26654a8a7d6d7e72021-11-30T17:03:34ZProspects for the development of adjuvant therapy for non-small cell lung cancer1815-14341815-144210.26442/18151434.2020.3.200339https://doaj.org/article/0ce8e5769b2f4663b26654a8a7d6d7e72020-11-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/52505/35952https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442The standard approach for stage IB and IIIIIA non-small cell lung cancer (NSCLC), associated with the high risk of relapse, after total lung resection is adjuvant chemotherapy, nowadays. The 5-year survival benefit for this approach is about 5%, and the risk of relapse reduces from 11 to 15%, depending on the stage. However, the relapse rate within 5 years after surgery and adjuvant chemotherapy in stage IBIIIA NSCLC is up to 70%. This fact requires the search for new solutions. The efficacy and safety profile of targeted drugs in metastatic NSCLC show the possibility to use them as adjuvant therapy in the early stages of the disease. This approach was actively studied in patients with mutations in the EGFR gene, and the most promising were the results of the ADAURA trial, which had been studied the use of Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, as adjuvant therapy. The use of adjuvant targeted therapy in ALK-positive patients is currently less studied and its efficacy will be determined as the results of the ALINA and ALCHEMIST trials are obtained.K. K. LaktionovA. M. KazakovE. V. ReutovaM. S. ArdzinbaA. L. ArzumanianIP Habib O.N.articlenon-small cell lung canceradjuvant targeted therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 3, Pp 85-87 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	non-small cell lung cancer adjuvant targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-small cell lung cancer adjuvant targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 K. K. Laktionov A. M. Kazakov E. V. Reutova M. S. Ardzinba A. L. Arzumanian Prospects for the development of adjuvant therapy for non-small cell lung cancer
description	The standard approach for stage IB and IIIIIA non-small cell lung cancer (NSCLC), associated with the high risk of relapse, after total lung resection is adjuvant chemotherapy, nowadays. The 5-year survival benefit for this approach is about 5%, and the risk of relapse reduces from 11 to 15%, depending on the stage. However, the relapse rate within 5 years after surgery and adjuvant chemotherapy in stage IBIIIA NSCLC is up to 70%. This fact requires the search for new solutions. The efficacy and safety profile of targeted drugs in metastatic NSCLC show the possibility to use them as adjuvant therapy in the early stages of the disease. This approach was actively studied in patients with mutations in the EGFR gene, and the most promising were the results of the ADAURA trial, which had been studied the use of Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, as adjuvant therapy. The use of adjuvant targeted therapy in ALK-positive patients is currently less studied and its efficacy will be determined as the results of the ALINA and ALCHEMIST trials are obtained.
format	article
author	K. K. Laktionov A. M. Kazakov E. V. Reutova M. S. Ardzinba A. L. Arzumanian
author_facet	K. K. Laktionov A. M. Kazakov E. V. Reutova M. S. Ardzinba A. L. Arzumanian
author_sort	K. K. Laktionov
title	Prospects for the development of adjuvant therapy for non-small cell lung cancer
title_short	Prospects for the development of adjuvant therapy for non-small cell lung cancer
title_full	Prospects for the development of adjuvant therapy for non-small cell lung cancer
title_fullStr	Prospects for the development of adjuvant therapy for non-small cell lung cancer
title_full_unstemmed	Prospects for the development of adjuvant therapy for non-small cell lung cancer
title_sort	prospects for the development of adjuvant therapy for non-small cell lung cancer
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/0ce8e5769b2f4663b26654a8a7d6d7e7
work_keys_str_mv	AT kklaktionov prospectsforthedevelopmentofadjuvanttherapyfornonsmallcelllungcancer AT amkazakov prospectsforthedevelopmentofadjuvanttherapyfornonsmallcelllungcancer AT evreutova prospectsforthedevelopmentofadjuvanttherapyfornonsmallcelllungcancer AT msardzinba prospectsforthedevelopmentofadjuvanttherapyfornonsmallcelllungcancer AT alarzumanian prospectsforthedevelopmentofadjuvanttherapyfornonsmallcelllungcancer
_version_	1718406425746604032

Prospects for the development of adjuvant therapy for non-small cell lung cancer

Ejemplares similares